Font Size: 

Incidence of hyperglycaemia as an adverse effect is highest following glucocorticoid use in rheumatoid arthritis patients. It has potential to elevate the risk of comorbidities, length of stay, and severity of the disease. Analysing the causes of adverse effects is challenging due to the scarcity of adverse effect monitoring data. Objective study to determine the impact and correlation of glucocorticoid administration that induced hyperglycaemia. Study design used retrospective cross-sectional study. The population is RSUP Dr. Kariadi patients aged >18 years with rheumatoid arthritis disease without DM comorbidity who received glucocorticoid and blood glucose examination. The data were statistically analyzed using chi-square to determine impact to incidence adverse effect hyperglycemia and logistic regression analysis to determine correlation with adverse effect. The clinical data of 97 patients between 2023-2024, 47 patients with hyperglycemia and 50 without hyperglycemia. Types of glucocorticoids (p=0.032), duration (p=0,006) and route administration (p=0,000) are significantly impacted to the incidence of adverse effect hyperglycemia. The route of administration showed the most correlation with glucocorticoid induced hyperglycemia in rheumatoid arthritis patients (OR 1.052; 95% CI 0.499-2.217). Collaborative effort between physicians and pharmacists needs to monitor and reduce the incidence of hyperglycemia.

glucocorticoid; adverse effect; hyperglycemia; rheumatoid arthritis, pharmacovigilance